Curavit’s Destiny Davis Named Among 1nHealth’s “25 for 25” Patient Engagement Leaders

Boston, MA - June 16, 2025 - Curavit Clinical Research proudly announces that Destiny Davis, a key member of its clinical operations team, has been recognized by 1nHealth as one of the "Patient Engagement Leaders Making an Impact: 25 for 25."

Destiny's leadership in decentralized clinical trials (DCTs) has helped Curavit optimize its Virtual Clinical Site (VCS), improve operational efficiency, and most importantly, enhance the patient experience. Her innovative use of data analytics to monitor engagement and proactively address challenges ensures that patients remain at the center of every trial.

"We're incredibly proud of Destiny's well-deserved recognition," said Curavit's President and Co-founder, Dave Hanaman. "Her passion for patient-centric innovation perfectly reflects Curavit's mission to make clinical research more accessible and effective."

For more information and to see the full list of honorees, visit: https://www.1nhealth.com/destiny-davis/

About Curavit Clinical Research
Curavit Clinical Research is a CRO with an AI-enabled Virtual Clinical Site that delivers innovation throughout a clinical trial. By partnering with leading clinical service and technology providers, they deliver seamless, interoperable studies that accelerate timelines, improve data quality, and enhance the participant experience. Curavit's flexible Virtual Clinical Site supports efficient, and future-ready clinical research.